Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Nangalia, C. Massie, E. Baxter, Francesca Nice, G. Gundem, D. Wedge, E. Avezov, Juan Li, K. Kollmann, D. Kent, Athar Aziz, A. Godfrey, Jonathon Hinton, I. Martincorena, P. Loo, A. Jones, P. Guglielmelli, P. Tarpey, H. Harding, J. Fitzpatrick, C. Goudie, Christina Ortmann, S. Loughran, K. Raine, David Jones, A. Butler, J. Teague, S. O'meara, Stuart Mclaren, M. Bianchi, Y. Silber, D. Dimitropoulou, D. Bloxham, L. Mudie, M. Maddison, B. Robinson, C. Keohane, C. Maclean, K. Hill, K. Orchard, S. Tauro, Ming-Qing Du, M. Greaves, D. Bowen, B. Huntly, C. Harrison, Nicholas Cross, D. Ron, A. Vannucchi, E. Papaemmanuil, P. Campbell, A. Green (2013)
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.The New England journal of medicine, 369 25
Biquan Luo, Amy Lee (2013)
The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapiesOncogene, 32
T. Klampfl, H. Gisslinger, A. Harutyunyan, Harini Nivarthi, E. Rumi, J. Milosevic, Nicole Them, T. Berg, B. Gisslinger, D. Pietra, Doris Chen, G. Vladimer, K. Bagienski, C. Milanesi, I. Casetti, Emanuela Sant'Antonio, V. Ferretti, C. Elena, Fiorella Schischlik, Ciara Cleary, M. Six, M. Schalling, Andreas Schönegger, C. Bock, L. Malcovati, C. Pascutto, G. Superti-Furga, M. Cazzola, R. Kralovics (2013)
Somatic mutations of calreticulin in myeloproliferative neoplasms.The New England journal of medicine, 369 25
Wenjuan Mo, Jiyuan Zhang, Xia Li, Delong Meng, Yun Gao, Shu Yang, Xuechao Wan, Caihong Zhou, Fenghua Guo, Yan Huang, Stefano Amente, E. Avvedimento, Yi Xie, Yao Li (2013)
Identification of Novel AR-Targeted MicroRNAs Mediating Androgen Signalling through Critical Pathways to Regulate Cell Viability in Prostate CancerPLoS ONE, 8
M. Michalak, J. Groenendyk, É. Szabó, L. Gold, M. Opas (2009)
Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum.The Biochemical journal, 417 3
H. Kourie, L. Ameye, M. Paesmans, D. Bron (2016)
Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.Clinical lymphoma, myeloma & leukemia, 16 5
Wen-An Wang, J. Groenendyk, M. Michalak (2012)
Calreticulin signaling in health and disease.The international journal of biochemistry & cell biology, 44 6
N. Shinton (2007)
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
P. Campbell, L. Scott, G. Buck, K. Wheatley, C. East, J. Marsden, Audrey Duffy, E. Boyd, A. Bench, M. Scott, G. Vassiliou, D. Milligan, Steve Smith, W. Erber, D. Bareford, B. Wilkins, J. Reilly, C. Harrison, A. Green (2005)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyThe Lancet, 366
L. Pieri, C. Paoli, U. Arena, F. Marra, F. Mori, M. Zucchini, S. Colagrande, A. Castellani, A. Masciulli, V. Rosti, V. Stefano, S. Betti, G. Finazzi, M. Ferrari, E. Rumi, M. Ruggeri, I. Nichele, P. Guglielmelli, R. Fjerza, C. Mannarelli, T. Fanelli, Lucia Merli, Giuditta Fattori, M. Massa, G. Cimino, A. Rambaldi, G. Barosi, M. Cazzola, T. Barbui, A. Vannucchi (2017)
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasmsAmerican Journal of Hematology, 92
R. Rampal, R. Rampal, F. Al-Shahrour, O. Abdel-Wahab, O. Abdel-Wahab, Jay Patel, J. Brunel, C. Mermel, C. Mermel, A. Bass, A. Bass, J. Pretz, J. Pretz, Jihae Ahn, Todd Hricik, O. Kilpivaara, M. Wadleigh, L. Busque, D. Gilliland, T. Golub, T. Golub, T. Golub, B. Ebert, B. Ebert, R. Levine, R. Levine (2014)
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.Blood, 123 22
Lijuan Han, C. Schubert, J. Köhler, M. Schemionek, S. Isfort, T. Brümmendorf, S. Koschmieder, N. Chatain (2016)
Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretionJournal of Hematology & Oncology, 9
A. Tefferi, T. Lasho, C. Finke, R. Knudson, R. Ketterling, C. Hanson, M. Maffioli, D. Caramazza, F. Passamonti, A. Pardanani (2014)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisonsLeukemia, 28
F. Takeshita, Lubna Patrawala, M. Osaki, Ryou-u Takahashi, Yusuke Yamamoto, N. Kosaka, Masaki Kawamata, K. Kelnar, A. Bader, D. Brown, T. Ochiya (2010)
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes.Molecular therapy : the journal of the American Society of Gene Therapy, 18 1
F. Passamonti, M. Maffioli (2016)
Update from the latest WHO classification of MPNs: a user's manual.Hematology. American Society of Hematology. Education Program, 2016 1
B. Scott, T. Gooley, M. Sorror, Andrew Rezvani, M. Linenberger, J. Grim, B. Sandmaier, D. Myerson, Tom Chauncey, R. Storb, V. Buxhofer-Ausch, J. Radich, F. Appelbaum, H. Deeg (2012)
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.Blood, 119 11
Zhuang Lin, Yan Ma, Qian Wang, Jing Zhang, Chen Zhu, Lu Zhang, Xiao-ping Xu (2016)
Atg3 Overexpression Enhances Bortezomib-Induced Cell Death in SKM-1 CellPLoS ONE, 11
N. Lavi (2014)
Calreticulin Mutations in Myeloproliferative NeoplasmsRambam Maimonides Medical Journal, 5
C. Pocanschi, G. Kozlov, U. Brockmeier, Achim Brockmeier, David Williams, K. Gehring (2011)
Structural and Functional Relationships between the Lectin and Arm Domains of Calreticulin*The Journal of Biological Chemistry, 286
T. Barbui, J. Thiele, A. Vannucchi, A. Tefferi (2015)
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisBlood Cancer Journal, 5
A. Tefferi, T. Lasho, C. Finke, Alem Belachew, E. Wassie, R. Ketterling, C. Hanson, A. Pardanani (2014)
Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impactLeukemia, 28
S. Khan, A. Jankowska, R. Mahfouz, A. Dunbar, Y. Sugimoto, N. Hosono, Zhenbo Hu, V. Cheriyath, S. Vatolin, B. Przychodzen, F. Reu, Y. Saunthararajah, C. O'keefe, M. Sekeres, A. List, A. Moliterno, M. McDevitt, J. Maciejewski, H. Makishima (2013)
Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignanciesLeukemia, 27
Ruey-Hwang Chou, Yung-Luen Yu, M. Hung (2011)
The roles of EZH2 in cell lineage commitment.American journal of translational research, 3 3
Chao Sun, Sujiang Zhang, Jianyong Li (2015)
Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutationsLeukemia & Lymphoma, 56
Michael Garbati, Catherine Welgan, Sally Landefeld, L. Newell, A. Agarwal, J. Dunlap, T. Chourasia, Hyunjung Lee, J. Elferich, E. Traer, R. Rattray, Michael Cascio, R. Press, G. Bagby, J. Tyner, B. Druker, K. Dao (2016)
Mutant calreticulin‐expressing cells induce monocyte hyperreactivity through a paracrine mechanismAmerican Journal of Hematology, 91
A. Tefferi (2016)
Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 91
T. Ernst, A. Chase, J. Score, Claire Hidalgo-Curtis, C. Bryant, A. Jones, K. Waghorn, K. Zoi, F. Ross, A. Reiter, A. Hochhaus, H. Drexler, A. Duncombe, F. Cervantes, D. Oscier, J. Boultwood, F. Grand, N. Cross (2010)
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disordersNature Genetics, 42
N. Polverelli, M. Breccia, G. Benevolo, B. Martino, A. Tieghi, R. Latagliata, E. Sabattini, M. Riminucci, L. Godio, L. Catani, M. Nicolosi, M. Perricone, D. Sollazzo, G. Colafigli, A. Campana, F. Merli, U. Vitolo, G. Alimena, G. Martinelli, R. Lewis, N. Vianelli, M. Cavo, F. Palandri (2017)
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patientsAmerican Journal of Hematology, 92
Chunjiao Song, Chen Huan, ChaoYang Xu, Ru Guomei (2014)
Uncovering the Roles of miRNAs and Their Relationship with Androgen Receptor in Prostate CancerIubmb Life, 66
J. Score, Claire Hidalgo-Curtis, A. Jones, N. Winkelmann, A. Skinner, D. Ward, K. Zoi, T. Ernst, F. Stegelmann, K. Döhner, A. Chase, N. Cross (2012)
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.Blood, 119 5
Jianquan Guo, Xuemei Huang, Hui Wang, Huanjie Yang (2015)
Celastrol Induces Autophagy by Targeting AR/miR-101 in Prostate Cancer CellsPLoS ONE, 10
Anne Laugesen, Jonas Højfeldt, K. Helin (2016)
Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer.Cold Spring Harbor perspectives in medicine, 6 9
S. Verstovsek, R. Mesa, J. Gotlib, R. Levy, Vikas Gupta, J. Dipersio, J. Catalano, M. Deininger, Carole Miller, R. Silver, M. Talpaz, E. Winton, J. Harvey, M. Arcasoy, E. Hexner, R. Lyons, R. Paquette, A. Raza, K. Vaddi, S. Erickson‐Viitanen, I. Koumenis, William Sun, V. Sandor, H. Kantarjian (2012)
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.The New England journal of medicine, 366 9
James Holaska, B. Black, D. Love, J. Hanover, J. Leszyk, B. Paschal (2001)
Calreticulin Is a Receptor for Nuclear ExportThe Journal of Cell Biology, 152
Marito Araki, Yinjie Yang, Nami Masubuchi, Yumi Hironaka, Hiraku Takei, S. Morishita, Yoshihisa Mizukami, Shin Kan, Shuichi Shirane, Y. Edahiro, Yoshitaka Sunami, A. Ohsaka, N. Komatsu (2016)
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.Blood, 127 10
Zhiyuan Wu, Xin-ju Zhang, Xiao Xu, Yuming Chen, Tingting Hu, Z. Kang, Shibao Li, Hua Wang, Wei-wei Liu, Xiaochao Ma, M. Guan (2014)
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasmsJournal of Hematology & Oncology, 7
A Laugesen, JW Højfeldt, K Helin (2016)
Role of the polycomb repressive complex 2 (PRC2) in transcriptional regulation and cancerCSH PERSPECT MED, 6
C. Harrison, J. Kiladjian, H. Al-Ali, H. Gisslinger, R. Waltzman, V. Stalbovskaya, M. Mcquitty, D. Hunter, R. Levy, L. Knoops, F. Cervantes, A. Vannucchi, T. Barbui, G. Barosi (2012)
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.The New England journal of medicine, 366 9
H. Andrikovics, Tunde Krahling, K. Balassa, G. Halm, A. Bors, Magdalena Koszarska, Á. Bátai, J. Dolgos, J. Csomor, M. Egyed, A. Sípos, P. Reményi, A. Tordai, T. Masszi (2014)
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutationsHaematologica, 99
G. Sashida, A. Iwama (2016)
Multifaceted role of the polycomb-group gene EZH2 in hematological malignanciesInternational Journal of Hematology, 105
A. Vannucchi, G. Rotunno, N. Bartalucci, G. Raugei, V. Carrai, M. Balliu, C. Mannarelli, A. Pacilli, L. Calabresi, R. Fjerza, L. Pieri, A. Bosi, R. Manfredini, P. Guglielmelli (2014)
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic valueLeukemia, 28
U. Gergis, E. Kuriakose, T. Shore, S. Mayer, T. Mark, R. Pearse, M. Schuster, E. Feldman, G. Roboz, E. Ritchie, J. Scandura, Hanhan Wang, X. Zhou, R. Silver, K. Besien (2016)
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.Clinical lymphoma, myeloma & leukemia, 16 5
JW Vardiman, J Thiele, DA Arber, RD Brunning, MJ Borowitz, A Porwit, NL Harris, MM Beau, E Hellstrom-Lindberg, A Tefferi, CD Bloomfield (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesBlood, 114
J. Vardiman, J. Thiele, D. Arber, R. Brunning, M. Borowitz, A. Porwit, N. Harris, M. Beau, E. Hellström-Lindberg, A. Tefferi, C. Bloomfield (2009)
The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia : Rationale and Important Changes
Nienke Vries, D. Hulsman, W. Akhtar, Johann Jong, D. Miles, M. Blom, O. Tellingen, J. Jonkers, M. Lohuizen (2015)
Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression.Cell reports, 10 3
E. Rumi, D. Pietra, C. Pascutto, P. Guglielmelli, A. Martínez‐Trillos, I. Casetti, D. Colomer, L. Pieri, M. Pratcorona, G. Rotunno, Emanuela Sant'Antonio, M. Bellini, C. Cavalloni, C. Mannarelli, C. Milanesi, E. Boveri, V. Ferretti, C. Astori, V. Rosti, F. Cervantes, G. Barosi, A. Vannucchi, M. Cazzola (2014)
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.Blood, 124 7
A. Fendler, C. Stephan, G. Yousef, K. Jung (2011)
MicroRNAs as regulators of signal transduction in urological tumors.Clinical chemistry, 57 7
(2010)
MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β
Primary myelofibrosis (PMF) is one of the BCR/ABL-negative myeloproliferative neoplasms (MPNs), characterized by the diffuse fibrous hyperproliferation, bone marrow osteosclerosis, extramedullary hematopoiesis, and marked splenomegaly. The patients with PMF have an insidious onset, a long duration of clinical course, and the deteriorated quality of life. It has been reported that the CALR gene 9 exon mutations were detected in 25–30% PMF patients, particularly as high as 80% in the JAK2/MPL-negative ones. As the second most common mutation in BCR/ABL-negative MPNs, CALR mutation has been included in the latest World Health Organization (WHO) classification criteria as one of the main diagnostic criteria for both essential thrombocythemia (ET) and PMF. Moreover, the CALR mutations indicated a favorable prognosis, which the mechanism is still under investigation. It was demonstrated that a characterized high expression of EZH2 and SUZ12 in CALR-mutated patients. Taking EZH2 as the research entry point, we initially discussed the mechanism that the CALR-positive patients with PMF exhibited a better prognosis in the current study.
Annals of Hematology – Springer Journals
Published: Mar 20, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.